DE1106765B - Process for the preparation of substituted benzimidazoles - Google Patents

Process for the preparation of substituted benzimidazoles

Info

Publication number
DE1106765B
DE1106765B DESCH27821A DESC027821A DE1106765B DE 1106765 B DE1106765 B DE 1106765B DE SCH27821 A DESCH27821 A DE SCH27821A DE SC027821 A DESC027821 A DE SC027821A DE 1106765 B DE1106765 B DE 1106765B
Authority
DE
Germany
Prior art keywords
general formula
hydrogen
morpholine
known per
given above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DESCH27821A
Other languages
German (de)
Other versions
DE1889239U (en
Inventor
Dr Helmer Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DESCH27821A priority Critical patent/DE1106765B/en
Publication of DE1106765B publication Critical patent/DE1106765B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Verfahren zur Herstellung substituierter Benzimidazole Zusatz zum Patent 1078132 In der deutschen Patentschrift 1078132 ist ein Verfahren zur Herstellung substituierter Benzimidazole der allgemeinen Formel beschrieben, worin R1 Alkyl, R2 und R3 die Atomgruppierung - CH2 - CH2 - OH oder R2 die Atomgruppierung - CH2 - CH2 - OH und R3 Wasserstoff oder R2 und R3 zusammen mit dem Stickstoffatom den Morpholinrest bedeuten und R4 Wasserstoff oder die Nitrogruppe darstellt. Diese z. B. als Monochlorhydrate angewandten wirksamen Produkte haben entzündungshemmende und analgetische Wirkung.Process for the preparation of substituted benzimidazoles Addition to the patent 1078132 In the German patent 1078132 there is a process for the preparation of substituted benzimidazoles of the general formula where R1 is alkyl, R2 and R3 is the atomic grouping - CH2 - CH2 - OH or R2 is the atomic grouping - CH2 - CH2 - OH and R3 is hydrogen or R2 and R3 together with the nitrogen atom is the morpholine radical and R4 is hydrogen or the nitro group. This z. Effective products used, for example, as monochlorohydrates have anti-inflammatory and analgesic effects.

Es wurde nun gefunden, daß durch Halogensubstitution im Benzolring (R4 = Halogen, vorzugsweise Chlor) überraschend eine antiphlogistische Wirkungssteigerung um etwa das Doppelte auftritt, wenngleich die halogenierte Substanz auch eine geringe (etwa 200/0ige) Toxizitätssteigerung erfährt, ist doch mit dem viel höheren therapeutischen Wirkungseffekt eine erhebliche Variationsbreite innerhalb der therapeutischen und toxischen Grenzen gegeben, wie aus der angeführten Tabelle klar ersichtlich: Ödem- Thera- peutischer LD50 hemmung Wirkungs- (%) effekt 1 -Äthyl-2-diäthanolamino- methyl-benzimidazol- monochlorhydrat . . 448 25 0,056 l-Äthyl-2-diäthanolamino- methyl-5-chlor-benz- imidazolmonochlor- hydrat . . ... 358 44 0,123 wobei die LD50 nach intravenöser Applikation an der Maus bestimmt wurde und die antiphlogistische Wirkung an der Ratte nach intraperitonealer Vorbehandlung mit der Wirksubstanz bei einer Dosis von 2.80 mg/kg beim Formalinödem getestet wurde.It has now been found that by halogen substitution in the benzene ring (R4 = halogen, preferably chlorine) there is surprisingly an anti-inflammatory increase in activity of about double, although the halogenated substance also experiences a slight (about 200/0) increase in toxicity, but is much higher with the one therapeutic effect, there is a considerable range of variation within the therapeutic and toxic limits, as can be clearly seen from the table below: Edema - more therapeutic LD50 inhibition effective (%) effect 1 -ethyl-2-diethanolamino- methyl benzimidazole monochlorohydrate. . 448 25 0.056 l-ethyl-2-diethanolamino- methyl-5-chloro-benz- imidazole monochlorine hydrate. . ... 358 44 0.123 the LD50 was determined after intravenous administration to the mouse and the anti-inflammatory effect was tested in the rat after intraperitoneal pretreatment with the active substance at a dose of 2.80 mg / kg in formalin edema.

Die erfindungsgemäß hergestellten Benzimidazole der allgemeinen Formel worin R1 Wasserstoff, Alkyl, R2 und R8 die Atomgruppierung - CH2 - CH2 - OH oder R2 die Atomgruppierung - CH2 - CH2 - OH und R3 Wasserstoff oder R2 und R3 zusammen mit dem Stickstoffatom den Morpholinrest bedeuten, werden, wie in der Patentschrift 1078132 beschrieben, dargestellt: Man setzt 2-Halogenmethyl-5-halogenbenzimidazole der allgemeinen Formel worin R1 die oben angegebene Bedeutung hat, mit Äthanolamin, Diäthanolamin oder Morpholin um, oder man unterwirft Verbindungen der allgemeinen Formel worin R1 bis R3 ebenfalls die oben angegebene Bedeutung haben, der an sich bekannten Ringschlußreaktion zum Benzimidazol.The benzimidazoles of the general formula prepared according to the invention where R1 is hydrogen, alkyl, R2 and R8 are the atomic grouping - CH2 - CH2 - OH or R2 is the atomic grouping - CH2 - CH2 - OH and R3 is hydrogen or R2 and R3 together with the nitrogen atom are the morpholine radical, as described in patent 1078132 , shown: 2-Halomethyl-5-halobenzimidazoles of the general formula are used in which R1 has the meaning given above, with ethanolamine, diethanolamine or morpholine, or compounds of the general formula are subjected where R1 to R3 also have the meaning given above, the ring closure reaction known per se to form benzimidazole.

Die als Ausgangsprodukte benötigten 1-Alkyl-2-halogenmethyl-5-halogenbenzimidazole erhält man vorzugsweise aus handelsüblichem 2,6-Dichlor-nitrobenzol durch Umsetzung mit Alkylamin, anschließende Reduktion der Nitrogruppe mit Wasserstoff in Gegenwart von vorzugsweise Nickelkatalysatoren und schließlich Ringschlußreaktion mit Chloressigsäure zum l-Alkyl-2-chlormethyl-5-chlorbenzimidazol. The 1-alkyl-2-halomethyl-5-halobenzimidazoles required as starting materials is preferably obtained from commercially available 2,6-dichloro-nitrobenzene by reaction with alkylamine, subsequent reduction of the nitro group with hydrogen in the presence of preferably nickel catalysts and finally ring closure reaction with chloroacetic acid to the 1-alkyl-2-chloromethyl-5-chlorobenzimidazole.

Die neuen Benzimidazole kann man in an sich bekannter Weise in ihre Salze, besonders das Monochlorhydrat, überführen. The new benzimidazoles can be converted into theirs in a manner known per se Transfer salts, especially the monochlorohydrate.

Beispiel 1 1 -Äthyl-2-morpholinomethyl-5-chlorbenzimiclazol 4,3g 1-Äthyl-2-chlormethyl-5-chlorbenzimidazolwerden mit 20ml Benzol versetzt. Unter Rühren tropft man langsam 4,1 g Morpholin, die mit 5 ml verdünnt sind, hinzu, läßt dann über Nacht bei Raumtemperatur weiterreagieren und spült nun das Reaktionsgemisch mit Wasser und Benzol in einen Scheidetrichter über, wäscht die Benzolphase mit Wasser neutral und trocknet sie mit wasserfreiem Kaliumcarbonat. Nach dem Verdampfen des Benzols im Vakuum hinterbleibt ein fester Rückstand, der aus Methanol umkristallisiert wird und das reine 1 -Äthyl-2-morpholinomethyl-5-chlorbenzimidazol in einer Ausbeute von 630in der Theorie ergibt; F. 172 bis 175°C. Example 1 1-Ethyl-2-morpholinomethyl-5-chlorobenzimiclazole 4.3g 1-Ethyl-2-chloromethyl-5-chlorobenzimidazole are mixed with 20 ml of benzene. Under 4.1 g of morpholine, which are diluted with 5 ml, are slowly added dropwise while stirring then continue to react overnight at room temperature and now rinse the reaction mixture with water and benzene into a separating funnel, the benzene phase washes with it Water neutral and dry them with anhydrous potassium carbonate. After evaporation of the benzene in vacuo, a solid residue remains which is recrystallized from methanol and the pure 1-ethyl-2-morpholinomethyl-5-chlorobenzimidazole in one yield of 630 results in theory; 172-175 ° C.

Das aus der Base durch Behandlung mit der berechneten Menge Salzsäure hergestellte Monohydrochlorid schmilzt bei 222 bis 223"C. That from the base by treatment with the calculated amount of hydrochloric acid produced monohydrochloride melts at 222 to 223 "C.

Beispiel 2 1 -Äthyl-2-diäthanolaminomethyl-5-chlorbenzimidazol 4,3 g 1-Äthyl-2-chlormethyl-5-chlorbenzimidazol in 25 ml Chloroform werden tropfenweise und unter Rühren mit 5 g Diäthanolamin, die mit 5 ml Chloroform verdünnt sind, versetzt. Das Reaktionsgemisch läßt man nun über Nacht bei Raumtemperatur ausreagieren. Die Aufarbeitung erfolgt gemäß Beispiel 1. Das nach dem Verdampfen des Chloroforms erhaltene rohe 1-Äthyl-2-diäthylaminomethyl-5-chlorbenzimidazol fällt als feste Substanz in einer Ausbeute von 710in Theorie an. Die Rohbase wird aus Essigester umkristallisiert und schmilzt bei 133 bis 134,5"C. Example 2 1-Ethyl-2-diethanolaminomethyl-5-chlorobenzimidazole 4.3 g of 1-ethyl-2-chloromethyl-5-chlorobenzimidazole in 25 ml of chloroform are added dropwise and 5 g of diethanolamine diluted with 5 ml of chloroform are added while stirring. The reaction mixture is then allowed to react to completion overnight at room temperature. the Work-up is carried out as in Example 1. That obtained after evaporation of the chloroform Crude 1-ethyl-2-diethylaminomethyl-5-chlorobenzimidazole falls as a solid Substance in a yield of 710 in theory. The raw base is recrystallized from ethyl acetate and melts at 133 to 134.5 "C.

Das Monohydrochlorid wird gemäß Beispiel 1 dargestellt; F. 110,5 bis 111,5"C. The monohydrochloride is prepared according to Example 1; F. 110.5 to 111.5 "C.

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung substituierter Benzimidazole mit entzündungshemmenden und analgetischen Eigenschaften der allgemeinen Formel worin Hal Halogen, insbesondere Chlor, Rl Wasserstoff oder Alkyl, R2 und R3 die Atomgruppierung - CH2 - CH2 - OH oder R2 die Atomgruppierung - CH2 - CH2 - OH und Ra Wasserstoff oder R2 und R3 zusammen mit dem Stickstoffatom den Morpholinrest bedeuten, gemäß Hauptpatent 1078132, dadurch gekennzeichnet, daß man a) 2-Halogenmethyl-5-halogenbenzimidazole der allgemeinen Formel worin R1 die oben angegebene Bedeutung hat, mit Äthanolamin, Diäthanolamin oder Morpholin umsetzt, oder daß man b) Verbindungen der allgemeinen Formel worin R1 bis R3 ebenfalls die oben angegebene Bedeutung haben, der an sich bekannten Ringschlußreaktion zum Benzimidazol unterwirft und gegebenenfalls die so erhaltenen Produkte in an sich bekannter Weise in die entsprechenden wasserlöslichen Säureadditionssalze, vorzugsweise in das Monochlorhydrat, überführt.PATENT CLAIM: Process for the production of substituted benzimidazoles with anti-inflammatory and analgesic properties of the general formula where Hal is halogen, in particular chlorine, Rl is hydrogen or alkyl, R2 and R3 is the atomic grouping - CH2 - CH2 - OH or R2 is the atomic grouping - CH2 - CH2 - OH and Ra is hydrogen or R2 and R3 together with the nitrogen atom is the morpholine residue, according to the main patent 1078132, characterized in that a) 2-halomethyl-5-halobenzimidazoles of the general formula in which R1 has the meaning given above, is reacted with ethanolamine, diethanolamine or morpholine, or that b) compounds of the general formula where R1 to R3 also have the meaning given above, subjects the ring closure reaction to give benzimidazole, which is known per se, and optionally converts the products thus obtained, in a manner known per se, into the corresponding water-soluble acid addition salts, preferably into the monochlorohydrate.
DESCH27821A 1960-04-28 1960-04-28 Process for the preparation of substituted benzimidazoles Pending DE1106765B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DESCH27821A DE1106765B (en) 1960-04-28 1960-04-28 Process for the preparation of substituted benzimidazoles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DESCH27821A DE1106765B (en) 1960-04-28 1960-04-28 Process for the preparation of substituted benzimidazoles

Publications (1)

Publication Number Publication Date
DE1106765B true DE1106765B (en) 1961-05-18

Family

ID=7430906

Family Applications (1)

Application Number Title Priority Date Filing Date
DESCH27821A Pending DE1106765B (en) 1960-04-28 1960-04-28 Process for the preparation of substituted benzimidazoles

Country Status (1)

Country Link
DE (1) DE1106765B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1241286B (en) * 1963-08-21 1967-05-24 John Deere Lanz Ag Hydraulic servo device for vehicle steering

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1241286B (en) * 1963-08-21 1967-05-24 John Deere Lanz Ag Hydraulic servo device for vehicle steering

Similar Documents

Publication Publication Date Title
DE2503815C2 (en) Indazole derivatives, processes for their preparation and pharmaceuticals
DE1493579B1 (en) Process for the preparation of new pharmaceutically valuable compounds
DE1695780A1 (en) Process for the preparation of new N-alkyl-3,1-benzoxain-2-ones
DE2458638C2 (en) 4'-substituted 2-methyl-3-piperidinopropiophenone derivatives, processes for their production and pharmacological preparations which contain them
DE1212090B (en) Process for the preparation of 10- (piperazinopropyl) -3-trifluoromethyl-phenothiazine compounds and their salts
DE941288C (en) Process for the preparation of substituted 2-imino-4-thiazolines or of salts thereof or of substituted 2-aminothiazoles
DE1106765B (en) Process for the preparation of substituted benzimidazoles
DE946058C (en) Process for the preparation of 3-aminoindanes
DE1468517B1 (en) Oestran series steroids and process for their manufacture
DE2530768C3 (en) PhenoxyaUcylaminpyridyläther, process for their production and pharmaceutical preparations containing them
DE1235929B (en) Process for the preparation of 2- (2'-pyrazinyl) benzimidazole and its salts
DE851066C (en) Process for the production of antihistaminic substances
DE2217202C3 (en) 5-substituted benzophenone hydrazone compounds, processes for their preparation and pharmaceutical preparations containing these compounds
AT221495B (en) Process for the production of new dibenzocycloheptane derivatives and their salts or quaternary ammonium compounds
DE829894C (en) Process for the preparation of new derivatives of 1,8-naphthyridine-4-carboxylic acids
DE1921340C3 (en) 2-Phenyl-5-halo-pyrimidines substituted in the 4-position
DE1493174C (en) 6-chloro-1,2 alpha; 16.17 alphabismethylene delta high 4,6-pregnadiene-3,20-dione, a drug containing this compound and process for the preparation of 1,2 alpha; 16.17 alpha-bismethylene delta high 4,6-pregnadienes
DE1493579C (en) Process for the production of new pharmaceutically valuable compounds
AT227256B (en) Process for the production of new aminoindanes and their salts
AT288413B (en) Process for the production of new basic xanthone derivatives and their salts
AT216504B (en) Process for the preparation of new isoindoline derivatives
DE1200824B (en) Process for the preparation of 3, 5-dioxo-triazolidines
AT234691B (en) Process for the preparation of new piperidine derivatives
DE2403682C3 (en) S-methyl-Z-phenyl-S-benzothiazole n-acylic acid compounds and process for their preparation
DE1543224A1 (en) Dibenzocycloheptene derivatives